Pharmaceutical Formulations
This article was originally published in The Tan Sheet
Executive Summary
President and CEO Charles LaRosa retires, but remains on the OTC manufacturer's board of directors; no successor has been named. LaRosa also sits on CHPA's board. In addition, the Edison, N.J.-based firm failed to make Dec. 15 debenture interest payments but intends to make them the week of Jan. 10, within the 30-day grace period allowed before default is declared
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning